Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies?

Ann Oncol. 2016 Nov;27(11):2131-2133. doi: 10.1093/annonc/mdw283. Epub 2016 Aug 8.

Authors

G Roviello^{1

2}, D Generali^{2

3}

Affiliations

¹ Section of Pharmacology and University Center DIFF-Drug Innovation Forward Future, Department of Molecular and Translational Medicine, University of Brescia, Brescia giandomenicoroviello@gmail.com.
² Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona, Cremona.
³ Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

PMID: 27502707
DOI: 10.1093/annonc/mdw283

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Male
Neoplasm Grading*
Prostate-Specific Antigen
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant*

Substances

Prostate-Specific Antigen